Shares of Praxis Precision Medicines, Inc. (PRAX) are soaring 5.50% in intraday trading on Wednesday, following a positive initiation from Chardan Capital. The stock's significant jump comes as investors react to the new bullish stance from a respected research firm.
Chardan Capital has initiated coverage on Praxis Precision Medicines with a Buy rating, setting an ambitious price target of $80. This new target represents substantial upside potential from the stock's current trading levels, fueling investor optimism and driving the sharp increase in share price.
The positive sentiment from Chardan Capital aligns with the overall bullish view on Praxis Precision Medicines among Wall Street analysts. According to FactSet data, the company currently maintains an average rating of Buy from analysts, with a mean price target of $99.27. This consensus suggests that other analysts also see significant growth potential for the biopharmaceutical company, which specializes in developing therapies for central nervous system disorders.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。